- Мар. 31, 2023
- Transfer of FUJIFILM Healthcare Systems’ electronic medical record and medical-receipt systems related business to PHC Holdings’ subsidiary
- Дек. 20, 2022
- Fujifilm Announces Asset Purchase Agreement with Inspirata, Inc. to acquire the company’s Digital Pathology Business
- Дек. 14, 2022
- Fujifilm Invests in PhenoVista Biosciences from its Life Sciences Corporate Venture Capital Fund
- Окт. 6, 2022
- Fujifilm to establish its first Bio-CDMO site in Japan
- Июн. 30, 2022
- Fujifilm to Invest USD 1.6 billion to enhance and expand its global offering of cell culture manufacturing services
- Апр. 5, 2022
- Fujifilm Completes Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc.
- Мар. 22, 2022
-
Transfer of FUJIFILM Toyama Chemical's Radiopharmaceutical Business
Amendment in relation to a return of domestic marketing rights for a product - Янв. 27, 2022
- Fujifilm Expands its Advanced Therapies CDMO Business with the Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc.
- Сен. 2, 2021
- Transfer of FUJIFILM Toyama Chemical's Radiopharmaceutical Business to PeptiDream
- Авг. 31, 2021
- Launch of Therapeutic Radiopharmaceutical Product, Lutathera® Injection targeting neuroendocrine tumors in Japan (FUJIFILM Toyama Chemical)
- Июн. 29, 2021
- $850 Million USD (¥90 Billion Yen) investment in FUJIFILM Diosynth Biotechnologies to add additional development and manufacturing capacity
- Июн. 23, 2021
-
Marketing Authorization Granted for Lutathera® Injection in Japan
- The first approval in Japan for peptide receptor radionuclide treatment drug, providing a new therapeutic option for neuroendocrine tumors (FUJIFILM Toyama Chemical) - Мар. 31, 2021
- FUJIFILM Healthcare starts to operate as Fujifilm Group company
- Мар. 30, 2021
- Fujifilm launches “FUJIFILM COVID-19 Ag Test”, a SARS-CoV-2 antigen rapid diagnostic test with a highly-sensitive detection technology based on silver halide amplification, in Europe
- Мар. 19, 2021
- Fujifilm Selects North Carolina as the Location to Build the Largest Cell Culture Biopharmaceutical CDMO Facility in North America
- Фев. 18, 2021
- Notice Concerning the Completion Timing for the Acquisition of Hitachi’s Diagnostic Imaging-related Business
- Фев. 15, 2021
- Fujifilm Kyowa Kirin Biologics and Mylan EPD Announce Launch of “Adalimumab (Genetical Recombination) [Adalimumab Biosimilar 1]” in Japan
- Янв. 29, 2021
- Transfer of Shares in Japan Tissue Engineering Co., Ltd. to TEIJIN LIMITED
- Янв. 14, 2021
- Fujifilm and the Center for Advanced Biological Innovation and Manufacturing Announce 76 million USD in Funding for Manufacturing and Innovation Center
- Янв. 7, 2021
- Fujifilm to Invest Over 200 Billion yen (2 Billion USD) to Establish New Large-Scale Cell Culture Manufacturing Site for Biopharmaceuticals in the U.S.A.
Казахстан